Med Spas Under the Microscope – The View From The FDA
As regulatory scrutiny of medical aesthetics grows, med spas are increasingly under the microscope. As a practice owner and provider, it can be hard to stay informed in an ever-changing landscape.
When you join AmSpa in Vegas, you have the unique opportunity to hear answers straight from federal regulators. The FDA is coming to MSS!
Saturday, April 11 at Medical Spa Show
9 – 10am PT: Med Spas Under the Microscope – The View From The FDA
This session explores how the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) are approaching oversight of med spa specifically from a Federal regulatory and enforcement perspective, including an overview of the first regulatory inspection conducted, and first form 483 issued, at a MedSpa by FDA. Senior Regulatory Counsel from the FDA will break down Federal requirements for med spa owners with respect to prescription drugs and compounded medications.
Madison Dini, General Counsel for Lynch Regenerative Medicine will discuss the regulatory landscape of PDGF and clarify the legal boundaries that govern manufacturers.
Speakers: Madison Dini, JD, general counsel for Lynch Regenerative Medicine; Alex R. Thiersch, JD, founder and chairman of the American Med Spa Association (AmSpa); Aaron Weisbuch, JD, senior regulatory advisor in the FDA’s Center for Drug Evaluation and Research’s Office of Compliance. Moderator: John Rodriguez, co-founder, Ethos Medspa.
Join us for important conversations at Medical Spa Show, April 9 – 12, 2026 at the Wynn Las Vegas. Explore the conference agenda and save your seat by selecting your sessions in the MSS App!
